human pcs 130 010  (ATCC)

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Cellular viability of human astrocyte cells (( A ) 24 h, ( B ) 48 h) and lung smooth muscle cells (( C ) 24 h, ( D ) 48 h) after incubation with naked pND1 and the 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 nanocomplexes formulated at N/P ratio of 5 (pND1 = 1 µg). Non-transfected cells were used as a positive control (Control (+)) and cells treated with ethanol were used as a negative control (Control (−)). Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0,05; **** p ˂ 0.0001).

Article Snippet: Human astrocyte cell line (HA1800), lung smooth muscle cells, normal, human (PCS-130-010), and human embryonic kidney (HEK293T) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Incubation, Transfection, Positive Control, Control, Negative Control, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of FITC fluorescence intensity ((a.u)/µg Protein) in the lysosomes, cytosol, and mitochondria of human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 24 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 systems. All complexes were formulated with an N/P ratio = 5 (pND1 = 1 µg). Untreated cells and naked pND1 stained with FITC were used as controls. Data were analyzed by two-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0.05; ** p ˂ 0.01; *** p ˂ 0.001; **** p ˂ 0.0001).

Article Snippet: Human astrocyte cell line (HA1800), lung smooth muscle cells, normal, human (PCS-130-010), and human embryonic kidney (HEK293T) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Fluorescence, Transfection, Staining, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of ND1 protein levels (ng/mL) in human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 48 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1), and MTS–(KH) 9 /pND1 systems (pND1 = 1 µg for all). All complexes were formulated with an N/P ratio = 5. Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison tests (** p = 0.0041 ( A ) and 0.0015 ( B ),**** p ˂ 0.0001).

Article Snippet: Human astrocyte cell line (HA1800), lung smooth muscle cells, normal, human (PCS-130-010), and human embryonic kidney (HEK293T) cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Transfection, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Cellular viability of human astrocyte cells (( A ) 24 h, ( B ) 48 h) and lung smooth muscle cells (( C ) 24 h, ( D ) 48 h) after incubation with naked pND1 and the 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 nanocomplexes formulated at N/P ratio of 5 (pND1 = 1 µg). Non-transfected cells were used as a positive control (Control (+)) and cells treated with ethanol were used as a negative control (Control (−)). Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0,05; **** p ˂ 0.0001).

Article Snippet: Primary lung smooth muscle cells were maintained in vascular cell basal medium (ATCC, PCS-100-030) supplemented with 5% heat-inactivated FBS, 5% L-glutamine, 0.5 mL penicillin–streptomycin–amphotericin B solution (penicillin 10 units/mL, streptomycin 10 μg/mL and amphotericin B 25 ng/mL), 5 ng/mL of basic-fibroblasts growth factor (b-FGF), 5 ng/mL epidermal growth factor (EGF), 50 μg/mL of ascorbic acid, and 10 ng/mL of insulin.

Techniques: Incubation, Transfection, Positive Control, Control, Negative Control, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of FITC fluorescence intensity ((a.u)/µg Protein) in the lysosomes, cytosol, and mitochondria of human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 24 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1) and MTS–(KH) 9 /pND1 systems. All complexes were formulated with an N/P ratio = 5 (pND1 = 1 µg). Untreated cells and naked pND1 stained with FITC were used as controls. Data were analyzed by two-way ANOVA with Bonferroni’s multiple comparison test (ns—non-significant ( p > 0.05); * p ˂ 0.05; ** p ˂ 0.01; *** p ˂ 0.001; **** p ˂ 0.0001).

Article Snippet: Primary lung smooth muscle cells were maintained in vascular cell basal medium (ATCC, PCS-100-030) supplemented with 5% heat-inactivated FBS, 5% L-glutamine, 0.5 mL penicillin–streptomycin–amphotericin B solution (penicillin 10 units/mL, streptomycin 10 μg/mL and amphotericin B 25 ng/mL), 5 ng/mL of basic-fibroblasts growth factor (b-FGF), 5 ng/mL epidermal growth factor (EGF), 50 μg/mL of ascorbic acid, and 10 ng/mL of insulin.

Techniques: Fluorescence, Transfection, Staining, Comparison

Journal: Pharmaceutics

Article Title: Upgrading Mitochondria-Targeting Peptide-Based Nanocomplexes for Zebrafish In Vivo Compatibility Assays

doi: 10.3390/pharmaceutics16070961

Figure Lengend Snippet: Quantification of ND1 protein levels (ng/mL) in human astrocyte cells ( A ) and lung smooth muscle cells ( B ), after 48 h of transfection with 20% PEG–MTS–WRAP1/pND1 (PEG–MTS–W1/pND1), 20% PEG–MTS–WRAP5/pND1 (PEG–MTS–W5/pND1), and MTS–(KH) 9 /pND1 systems (pND1 = 1 µg for all). All complexes were formulated with an N/P ratio = 5. Data were analyzed by one-way ANOVA with Bonferroni’s multiple comparison tests (** p = 0.0041 ( A ) and 0.0015 ( B ),**** p ˂ 0.0001).

Article Snippet: Primary lung smooth muscle cells were maintained in vascular cell basal medium (ATCC, PCS-100-030) supplemented with 5% heat-inactivated FBS, 5% L-glutamine, 0.5 mL penicillin–streptomycin–amphotericin B solution (penicillin 10 units/mL, streptomycin 10 μg/mL and amphotericin B 25 ng/mL), 5 ng/mL of basic-fibroblasts growth factor (b-FGF), 5 ng/mL epidermal growth factor (EGF), 50 μg/mL of ascorbic acid, and 10 ng/mL of insulin.

Techniques: Transfection, Comparison